참고문헌 (75)

1. 1 Garcia A Fulton JE Jr Cosmetic denervation of the muscles of facial expression with botulinum toxin: a dose-response study Dermatol Surg 1996 22 39 43 8556256 

   상세보기

2. 2 Tsui JK Botulinum toxin as a therapeutic agent Pharmacol Ther 1996 72 13 24 8981568 

   상세보기

3. 3 Nigam PK Nigam A Botulinum toxin Indian J Dermatol 2010 55 8 14 20418969 

   상세보기

4. 4 Sellin LC The pharmacological mechanism of botulism Trends Pharmacol Sci 1985 6 80 2 

5. 5 Munchau A Bhatia KP Uses of botulinum toxin injection in medicine today BMJ 2000 320 161 5 10634738 

6. 6 Jankovic J Botulinum toxin in clinical practice J Neurol Neurosurg Psychiatry 2004 75 951 7 15201348 

   상세보기

7. 7 Guida S Farnetani F Nistico SP New trends in botulinum toxin use in dermatology Dermatol Pract Concept 2018 8 277 82 30479855 

   상세보기

8. 8 Harii K Kawashima M A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects Aesthetic Plast Surg 2008 32 724 30 18663516 

9. 9 Honeck P Weiss C Sterry W Reproducibility of a fourpoint clinical severity score for glabellar frown lines Br J Dermatol 2003 149 306 10 12932236 

   상세보기

10. 10 Carruthers JD Lowe NJ Menter MA Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines Plast Reconstr Surg 2003 112 1089 98 12973229 

11. 11 Won CH Lee HM Lee WS Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study Dermatol Surg 2013 39 1 Pt 2 171 8 23301821 

12. 12 Won CH Kim HK Kim BJ Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study Int J Dermatol 2015 54 227 34 25311357 

    상세보기

13. 13 Scott AB Botulinum toxin injection of eye muscles to correct strabismus Trans Am Ophthalmol Soc 1981 79 734 70 7043872 

    상세보기

14. 14 Dressler D Complete secondary botulinum toxin therapy failure in blepharospasm J Neurol 2000 247 809 10 11127541 

    상세보기

15. 15 Scott AB Kennedy RA Stubbs HA Botulinum A toxin injection as a treatment for blepharospasm Arch Ophthalmol 1985 103 347 50 3977705 

    상세보기

16. 16 Frueh BR Felt DP Wojno TH Treatment of blepharospasm with botulinum toxin: a preliminary report Arch Ophthalmol 1984 102 1464 8 6385932 

    상세보기

17. 17 Benecke R Clinical relevance of botulinum toxin immunogenicity BioDrugs 2012 26 e1 9 22385408 

    상세보기

18. 18 Hsieh PF Chiu HC Chen KC Botulinum toxin A for the treatment of overactive bladder Toxins (Basel) 2016 8 59 

    상세보기

19. 19 Dat A Chin M Skinner S Botulinum toxin therapy for chronic anal fissures: where are we at currently? ANZ J Surg 2017 87 E70 3 26423046 

    상세보기

20. 20 Camargo CH Cattai L Teive HA Pain relief in cervical dystonia with botulinum toxin treatment Toxins (Basel) 2015 7 2321 35 26110508 

    상세보기

21. 21 Bhidayasiri R Truong DD Evidence for effectiveness of botulinum toxin for hyperhidrosis J Neural Transm (Vienna) 2008 115 641 5 17885725 

22. 22 Ferrante FM Bearn L Rothrock R Evidence against trigger point injection technique for the treatment of cervicothoracic myofascial pain with botulinum toxin type A Anesthesiology 2005 103 377 83 16052120 

    상세보기

23. 23 Inoue K Fujinaga Y Watanabe T Molecular composition of Clostridium botulinum type A progenitor toxins Infect Immun 1996 64 1589 94 8613365 

    상세보기

24. 24 Sharma SK Singh BR Immunological properties of Hn-33 purified from type A Clostridium botulinum J Nat Toxins 2000 9 357 62 11126514 

    상세보기

25. 25 Kukreja RV Singh BR Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E Biochemistry 2007 46 14316 24 18004882 

26. 26 Kwak S Kang WH Rhee CH Comparative pharmacodynamics study of 3 different botulinum toxin type A preparations in mice Dermatol Surg 2020 46 e132 8 32251006 

    상세보기

27. 27 Bellows S Jankovic J Immunogenicity associated with botulinum toxin treatment Toxins (Basel) 2019 11 491 

    상세보기

28. 28 Dong M Yeh F Tepp WH SV2 is the protein receptor for botulinum neurotoxin A Science 2006 312 592 6 16543415 

    상세보기

29. 29 Pirazzini M Rossetto O Eleopra R Botulinum neurotoxins: biology, pharmacology, and toxicology Pharmacol Rev 2017 69 200 35 28356439 

    상세보기

30. 30 Dressler D Bigalke H Immunological aspects of botulinum toxin therapy Expert Rev Neurother 2017 17 487 94 27852103 

31. 31 Stanley EF Drachman DB Botulinum toxin blocks quantal but not non-quantal release of ACh at the neuromuscular junction Brain Res 1983 261 172 5 6301625 

    상세보기

32. 32 Kukreja R Chang TW Cai S Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins Toxicon 2009 53 616 24 19673075 

    상세보기

33. 33 Naumann M Boo LM Ackerman AH Immunogenicity of botulinum toxins J Neural Transm (Vienna) 2013 120 275 90 23008029 

34. 34 Hasegawa K Watanabe T Suzuki T A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms J Biol Chem 2007 282 24777 83 17581814 

    상세보기

35. 35 Ellenhorn MJ Barceloux DG Medical toxicology: diagnosis and treatment of human poisoning New York Elsevier 1988 1185 7 

36. 36 Fujinaga Y Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin J Biochem 2006 140 155 60 16954533 

    상세보기

37. 37 Park JY Sunga O Wanitphakdeedecha R Neurotoxin impurities: a review of threats to efficacy Plast Reconstr Surg Glob Open 2020 8 e2627 32095419 

    상세보기

38. 38 Ravenni R De Grandis D Mazza A Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence Neurol Sci 2013 34 1043 8 23576131 

    상세보기

39. 39 Carruthers J Fournier N Kerscher M The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine: a global, evidence-based botulinum toxin consensus education initiative Part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatol Surg 2013 39 3 Pt 2 510 25 

40. 40 Lorenc ZP Kenkel JM Fagien S Consensus panel’s assessment and recommendations on the use of 3 botulinum toxin type A products in facial aesthetics Aesthet Surg J 2013 33 1 Suppl 35S 40S 23515197 

41. 41 Krebs KM Lebeda FJ Comparison of the structural features of botulinum neurotoxin and NTNH, a non-toxic accessory protein of the progenitor complex Botulinum J 2008 1 116 34 

42. 42 Frevert J Content of botulinum neurotoxin in Botox ® /Vistabel ® , Dysport ® /Azzalure ® , and Xeomin ® /Bocouture ® Drugs R D 2010 10 67 73 20698714 

43. 43 Kerscher M Roll S Becker A Comparison of the spread of three botulinum toxin type A preparations Arch Dermatol Res 2012 304 155 61 22002325 

    상세보기

44. 44 Frevert J Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products Drugs R D 2015 15 1 9 25559581 

45. 45 Ohishi I Sugii S Sakaguchi G Oral toxicities of Clostridium botulinum toxins in response to molecular size Infect Immun 1977 16 107 9 326664 

    상세보기

46. 46 Chen F Kuziemko GM Stevens RC Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species Infect Immun 1998 66 2420 5 9596697 

    상세보기

47. 47 Frevert J Dressler D Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 2010 4 325 32 21209727 

    상세보기

48. 48 Johnson EA Bradshaw M Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective Toxicon 2001 39 1703 22 11595633 

    상세보기

49. 49 Grein S Mander GJ Taylor HV Xeomin ® is stable without refrigeration: Complexing proteins are not required for stability of botulinum neurotoxin type A preparations Toxicon 2008 51 Suppl 1 13 

50. 50 de Almeida AT De Boulle K Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications J Cosmet Laser Ther 2007 9 Suppl 1 17 22 17885882 

51. 51 Dodd SL Rowell BA Vrabas IS A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function Eur J Neurol 1998 5 181 6 10210830 

    상세보기

52. 52 Tang-Liu DD Aoki KR Dolly JO Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125Ibotulinum-free neurotoxin: time course of tissue distribution Toxicon 2003 42 461 9 14529727 

    상세보기

53. 53 Frevert J Xeomin is free from complexing proteins Toxicon 2009 54 697 701 19292989 

    상세보기

54. 54 Pingel J Nielsen MS Lauridsen T Injection of high dose botulinum-toxin A leads to impaired skeletal muscle function and damage of the fibrilar and non-fibrilar structures Sci Rep 2017 7 14746 29116170 

    상세보기

55. 55 Seo MS Kim YI Kang KK Comparison study of the response with botulinum toxin muscle injection in the ICR mice from three different sources Lab Anim Res 2019 35 11 32257899 

    상세보기

56. 56 Wang L Sun Y Yang W Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells Toxicon 2014 82 52 60 24560879 

    상세보기

57. 57 Goschel H Wohlfarth K Frevert J Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies. Therapeutic consequences Exp Neurol 1997 147 96 102 9294406 

    상세보기

58. 58 Sankhla C Jankovic J Duane D Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections Mov Disord 1998 13 150 4 9452341 

59. 59 Dressler D Bigalke H Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy Mov Disord 2002 17 170 3 11835457 

60. 60 Dressler D Clinical presentation and management of antibody-induced failure of botulinum toxin therapy Mov Disord 2004 19 Suppl 8 S92 100 15027060 

61. 61 Kromminga A Schellekens H Antibodies against erythropoietin and other protein-based therapeutics: an overview Ann N Y Acad Sci 2005 1050 257 65 16014541 

    상세보기

62. 62 Albrecht P Jansen A Lee JI High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy Neurology 2019 92 e48 54 30464031 

    상세보기

63. 63 Naumann M Carruthers A Carruthers J Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX ® ) across multiple indications Mov Disord 2010 25 2211 8 20737546 

64. 64 Rahman E Alhitmi HK Mosahebi A Immunogenicity to botulinum toxin type A: a systematic review with meta-analysis across therapeutic indications Aesthet Surg J 2022 42 106 20 33528495 

    상세보기

65. 65 Wang C Sun T Li H Hypersensitivity caused by cosmetic injection: systematic review and case report Aesthetic Plast Surg 2021 45 263 72 32206863 

66. 66 Moon IJ Chang SE Kim SD First case of anaphylaxis after botulinum toxin type A injection Clin Exp Dermatol 2017 42 760 2 28639343 

    상세보기

67. 67 Torres S Hamilton M Sanches E Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports Clin Cosmet Investig Dermatol 2013 7 11 7 

68. 68 Coleman WP 3rd Sattler G Weissenberger P Safety of incobotulinumtoxinA in the treatment of facial lines: results from a pooled analysis of randomized, prospective, controlled clinical studies Dermatol Surg 2017 43 Suppl 3 S293 303 33065955 

69. 69 Atassi MZ Basic immunological aspects of botulinum toxin therapy Mov Disord 2004 19 Suppl 8 S68 84 15027058 

70. 70 Dressler D Bigalke H Benecke R Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure J Neurol 2003 250 967 9 12928917 

    상세보기

71. 71 Dressler D Zettl U Benecke R Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure? Mov Disord 2000 15 1279 81 11104225 

72. 72 Hanna PA Jankovic J Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response Neurology 1998 50 1624 9 9633703 

73. 73 Gordon PH Gooch CL Greene PE Extensor digitorum brevis test and resistance to botulinum toxin type A Muscle Nerve 2002 26 828 31 12451609 

    상세보기

74. 74 Dressler D Bigalke H Rothwell JC The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans J Neurol 2000 247 630 2 11041331 

    상세보기

75. 75 Voller B Moraru E Auff E Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type A Mov Disord 2004 19 943 7 15300661